Anti-EGFR antibodies and uses thereof
US9132192B2 · kind B2 · utility
15Cited by
8References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2013 |
| Grant date | Sep 15, 2015 |
| Priority date | — |
| Expiry date | Jun 25, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.